Burkitt's lymphoma
ICD-10 C83.7ICD-11 2A85.6

Suspected Burkitt's Lymphoma With LDH Below 2× the Upper Limit of Normal and No Spontaneous Tumor Lysis Syndrome

Clinical Scenario

This protocol addresses patients with suspected Burkitt's lymphoma who do not have spontaneous tumor lysis syndrome (TLS) at presentation, do not have stage III or IV disease, and whose lactate dehydrogenase (LDH) has not reached twice the upper limit of normal.

Although LDH is below the high-risk threshold and spontaneous TLS is absent, treatment initiation in this setting carries a meaningful risk of inducing tumor lysis — making early preventive management essential.
Initial Approach

The management strategy in this scenario prioritises TLS prevention from the outset. Prophylactic intervention should begin promptly once Burkitt's lymphoma is suspected, with close serial monitoring of relevant laboratory values throughout. The complete structured protocol — including specific agents, monitoring parameters, and sequencing — is available below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2019004099

If BL is suspected, prophylactic allopurinol should be promptly initiated, and TLS laboratory values should be monitored closely.

TLS can also be induced with treatment initiation, thus requiring aggressive hydration and monitoring.

View source ↗